Myelofibrosis

Welcome to The Myelofibrosis Channel

Stay up to date with the latest news on this rare bone marrow malignancy with our expert-led video interviews, as well as podcasts and roundtable discussions. The Myelofibrosis Channel covers different pathways that have been explored to modify myelofibrosis, including novel targeted agents, and much more.

Incorporating novel agents for myelofibrosis in the pre- and post-transplant settings 1:56
Incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
Katja Sockel • 25 Apr 2023
Challenges in selecting patients with MF for SCT & using AI to determine the optimal timing for SCT 2:46
Challenges in selecting patients with MF for SCT & using AI to determine the optimal timing for SCT
Monia Marchetti • 26 Apr 2023
The role of transplantation in MPNs & factors to consider when selecting patients for transplant 1:39
The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison • 24 Apr 2023
Ruxolitinib combinations in patients with myelofibrosis 2:14
Ruxolitinib combinations in patients with myelofibrosis
Jean-Jacques Kiladjian • 26 Apr 2023
The rationale for combining magrolimab with ruxolitinib in myelofibrosis 1:16
The rationale for combining magrolimab with ruxolitinib in myelofibrosis
Ciro Rinaldi • 5 May 2023
Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible 2:09
Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible
Jean-Jacques Kiladjian • 26 Apr 2023
The role of allogeneic transplantation in myelofibrosis & patient eligibility for alloSCT 1:34
The role of allogeneic transplantation in myelofibrosis & patient eligibility for alloSCT
Jean-Jacques Kiladjian • 26 Apr 2023
The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies 1:20
The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies
Jean-Jacques Kiladjian • 26 Apr 2023
Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis 2:51
Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis
Jan Philipp Bewersdorf • 18 Apr 2023
Optimizing current treatment approaches in myelofibrosis 2:33
Optimizing current treatment approaches in myelofibrosis
Claire Harrison • 24 Apr 2023
Highlights at BSH 2023: addressing difficult scenarios in MPNs 2:50
Highlights at BSH 2023: addressing difficult scenarios in MPNs
Claire Harrison • 24 Apr 2023
Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis 3:35
Analysis from MOST: disease progression and leukemic transformation in lower-risk myelofibrosis
Rami Komrokji • 19 Dec 2022
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial 3:12
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial
Rami Komrokji • 19 Dec 2022
Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis 3:22
Phase I dose-escalation study of zelavespib in patients with relapsed myelofibrosis
Gary Schiller • 1 Dec 2022
Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis 2:40
Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
Harinder Gill • 10 Dec 2022
Phase II trial of KER-050 in patients with myelofibrosis 0:50
Phase II trial of KER-050 in patients with myelofibrosis
Claire Harrison • 12 Dec 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals